LIQUIDIA CORPORATION LQDA INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 57.2% Share Drop
For best results when printing this announcement, please click on link below: LIQUIDIA CORPORATION LQDA INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 57.2% Share Drop The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE FIRM’S INVESTIGATION ] What Happened? On September 30, 2026, the U.S. District Court for the District of Delaware found that Liquidia’s lead commercial product used to treat pulmonary hypertension, Yutrepia inhalation powder, infringed two of six claims of United Therapeutics Corporation’s ‘327 patent. The Court ruled that Yutrepia infringed claims 1 and 14 of the ‘327 patent, which cover the treatment of pulmonary hypertension with interstitial lung disease patients with inhaled treprostinil. In response to the ruling, Luiqidia CEO Roger Jeffs stated, “We respectfully disagree with the Court’s decision regarding claims 1 and 14 an
2% Share Drop The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE FIRM’S INVESTIGATION ] What Happened? S. District Court for the District of Delaware found that Liquidia’s lead commercial product used to treat pulmonary hypertension, Yutrepia inhalation powder, infringed two of six claims of United Therapeutics Corporation’s ‘327 patent.
The Court ruled that Yutrepia infringed claims 1 and 14 of the ‘327 patent, which cover the treatment of pulmonary hypertension with interstitial lung disease patients with inhaled treprostinil. 26 on September 30, 2026. What Should I Do? At this stage, no lawsuit has been filed.
The investigation is ongoing to determine whether claims may be brought under federal securities laws. com), or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost. [LEARN MORE ABOUT SECURITIES CLASS ACTIONS] Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.
Additional information about the firm can be found at Kirby McInerney LLP’s website This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. com: Kirby McInerney LLP Lauren Molinaro, Esq. com)